Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 620 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Providence Alaska Medical Center — Anchorage, Alaska
+ 200 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Locations: - Cedars-Sinai Medical Center — Los Angeles, California
- Jupiter Medical Center — Jupiter, Florida
- Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
+ 149 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- Cancer Treatment Center of America Phoenix — Goodyear, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
+ 48 more sites in the U.S.
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Locations: - Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
- Southern VA Health Care System /ID# 266254 — Tucson, Arizona
- UCSF FRESNO/Community Cancer Institute /ID# 270874 — Clovis, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Locations: - University of Alabama Hospital (UAB Hospital) — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
+ 18 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Locations: - Quetzal Site 1 — Duarte, California
- Quetzal Site 7 — Los Angeles, California
- Quetzal Site 5 — Stanford, California
+ 6 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into…
Sponsor: Moleculin Biotech, Inc.
NCT ID: NCT06788756
Locations: - Bioresearch Partners — Miami, Florida
- Augusta University - Georgia Cancer Center — Augusta, Georgia
- University of Nebraska Medical Center — Omaha, Nebraska
+ 3 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and a…
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT ID: NCT07223814
Locations: - US-San Francisco CA-UCSF — San Francisco, California
- US-Atlanta GA-EMORY — Atlanta, Georgia
- US-Kansas City KS-KUMC — Kansas City, Kansas
+ 3 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive ti…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07223021
Locations: - Memorial Sloan Kettering Cancer Center — New York, New York
- Cincinnati Children's Hospital Medical Center (Data Collection Only) — Cincinnati, Ohio
- Children's Hospital of Philadelphia (Data Collection Only) — Philadelphia, Pennsylvania
+ 2 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) …
Sponsor: BeOne Medicines
NCT ID: NCT07277231
Locations: - Stanford Cancer Institute — Palo Alto, California
- Northwestern University — Chicago, Illinois
- Fred Hutchinson Cancer Research Center — Seattle, Washington